Comparison of enalapril and valsartan in cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on high-sodium diet

British Journal of Pharmacology

Volumn 130, Issue 6, 2000, Pages 1339-1347

  Lassila, Markus ^b   Finckenberg, Piet ^b   Pere, Anna Kaisa ^a   Krogerus, Leena ^a   Ahonen, Juhani ^a   Vapaatalo, Heikki ^b   Nurminen, Marja Leena ^b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b Helsinki City Hospital ^*

Author keywords

Angiotensin II; Bradykinin; Cyclosporine A; Enalapril; Hypertension; Icatibant (HOE 140); Nephrotoxicity; Sodium; Valsartan

Indexed keywords

ANTIHYPERTENSIVE AGENT; BRADYKININ; BRADYKININ B2 RECEPTOR ANTAGONIST; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ICATIBANT; KININ; TISSUE KALLIKREIN; VALSARTAN;

ANIMAL EXPERIMENT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG EFFECT; FLUID INTAKE; FOOD INTAKE; HEART LEFT VENTRICLE HYPERTROPHY; HEART RATE; HYPERTENSION; KIDNEY FUNCTION; MALE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SYSTOLIC BLOOD PRESSURE; URINE VOLUME;

EID: 0008761345     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0703422     Document Type: Article

References (45)

1. ABASSI, Z.A., PIERUZZI, F., NAKHOUL, F. & KEISCR, H.R. (1996). Effects of cyclosporin A on the synthesis, excretion, and metabolism of endothelin in the rats. Hypertension, 27, 1140-1148.
2. AMUNDSEN, E., PUTTER, J., FRIBERGER, P., KNOS, M., LARSBRATEN, M. & CLAESON, G. (1979). Methods for determination of glandular kallikrein by means of chromogenic tripeptide substrate. In Kinins II Biochemistry, Pathophysiology and Clinical Aspects. ed. Fuji, Moriya, Suzuki pp. 83-93. Plenum Publishing Corp.
3. AUCH-SCHWELK, W., BOSSALLER, C., GÖTZE, S., THELEN, J. & FLECK, E. (1993). Endothelin and vascular smooth muscle function after chronic treatment with cyclosporin A. J. Cardiovasc. Pharm., 21, 435-440.
4. BAO, G., GOHLKE, P., QADRI, F. & UNGER, T. (1992). Chronic kinin receptor blockade attenuates the antihypertensive effect of ramipril. Hypertension, 20, 74-79.
5. BARTELS, H., BOHMER, M. & HEIERLI, C. (1972). Serum creatinine determination without protein precipitation. Clin. Chim. Acta., 37, 193-197.
6. BRUNNER, H.R., NUSSBERGER, J. & WEABER, B. (1993). Angiotensin II blockade compared with other pharmacological methods of inhibiting the renin-angiotensin system. J. Hypertens., 11, S53-S58.
7. BURDMANN, E.A., ANDOH, T.F., NAST, C.C., EVAN, A., CONNORS, B.A., COFFMAN, T.M., LINDSLEY, J. & BENNETT, W.M. (1995). Prevention of experimental cyclosporin-induced insterstitial fibrosis by losartan and enalapril. Am. J. Physiol., 269, F491-F499.
8. DENDORFER, A., HAUSER, W., FALIAS, D. & DOMINIAK, P. (1996). Bradykinin increases catecholamine release via B2 receptors. Eur. J. Physiol., 432 (3 suppl.), R99-R106.
9. EDWARDS, B.D., CHALMERS, R.J., O'DRISCOLL, J.B., MITCHELL, D.M., SMITH, R.J., LAWSON, R.S., TESTA, H.J. & BALLARDIE, F.W. (1994). Angiotensin II as a risk factor for cyclosporin nephrotoxicity in patients with psoriasis. Clin. Nephrol., 41, 350-356.
10. FAULDS, D., GOA, K.L. & BENFIELD, P. (1993). Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drug, 45, 953-1040.
11. GIACHELLI, C.M., PICHLER, R., LOMBARDI, D., DENHARDT, D.T., ALPERS, C.E., SCHWARZ, S.M. & JOHNSON, R.J. (1994). Osteopontin expression in angiotensin II-induced tubulointerstitial nephritis. Kidney Int., 45, 515-524.
12. GRIFFITHS, M.H., CROWE, A.V., PAPADAKI, L., BANNER, N.R., YACOB, M.H., THOMPSON, F.D. & NEILD, G.H. (1996). Cyclosporine nephrotoxicity in heart and lung transplant patients. Q.J.M., 89, 751-763.
13. HANNEDOUCHE, T.P., NATOV, S., BOITARD, C., LACOUR, B. & GRUNFELD, J.P. (1996). Angiotensin converting enzyme inhibition and chronic cyclosporine-induced renal dysfunction in type 1 diabetes. Nephrol. Dial. Transpant., 11, 673-678.
14. HAUSBERG, M., BARENBROCK, M., HOHAGE, H., MULLER, S., HEIDENREICH, S. & RAHN, K.-H. (1999). ACE inhibitor versus beta-blocker for the treatment of hypertension in renal allograft recipients. Hypertension, 33, 862-868.
15. HOLLENBERG, N., FISHER, N. & PRICE, D. (1998). Pathways for angiotensin II generation in intact human tissue; evidence from comparative pharmacological interruption of the renin system. Hypertension, 32, 387-392.
16. HOLWERDA, J.H., FOGARI, R., ANGELI, P., PORCELLATI, C., HERENG, C., ODDOUSTOCK, P., HEATH, R. & BODIN, F. (1996). Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J. Hypertens., 14, 1147-1151.
17. INAGAMI, T. (1999). Molecular biology and signalling of angiotensin receptors: an overview. J. Am. Nephrol., 10, S2-S7.
18. IWAI, J., KANAYAMA, Y., INOUE, N.N., OKAMURA, M. & TAKEDA, T. (1993). Increased endothelial gene expression of angiotensin ATI A receptor in cyclosporine induced hypertensive rats. Eur. J. Pharmacol., 248, 341-344.
19. KASKEL, F.J., DEVARAJAN, P., ARBEIT, L.A., PARTIN, J.S. & MOORE, L.C. (1987). Cyclosporine nephrotoxicity: sodium excretion, autoregulation, and angiotensin II. Am. J. Physiol., 252, F733-F742.
20. KON, V., HUNTLEY, T.E. & FOGO, A. (1995). Combined antagonism of endothelin A, B receptors links endothelin to vasoconstriction whereas angiotensin II effects fibrosis. Transplantation, 60, 89-95.
21. KURTZ, A., DELLA BRUNA, R. & KUHN, K. (1988). Cyclosporine A enhances renin secretion and production in isolated juxtaglomerular cells. Kidney Int., 33, 947-953.
22. LANESE, D.M. & CONGER, J.D. (1993). Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arteriolcs. J. Clin. Invest., 91, 2144-2149.
23. LINZ, W., WIEMER, G., GOHLKE, P., UNGER, T. & SCHÖLKENS, B. (1995). Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol. Rev., 47, 25-49.
24. LOWRY, O.H., ROSENBROUGH, N.J., FARR, A.L. & RANDALL, R.J. (1951). Protein measurement with the folin phenol reagent. J. Biol. Chem., 193, 265-275.
25. LUDBROOK, J. (1994). Repeated measurements and multiple comparisons in cardiovascular research. Cardiovascular Res., 28, 303-311.
26. MAJIMA, M. & KATORI, M. (1995). Approaches to the development of novel antihypertensive drugs: crucial role of the renal kallikrein system. Trends Pharmacol. Sci., 16, 239-246.
27. MASON, J. (1989). Pharmacology of cyclosporine (Sandimmune) VII. Pathophysiology and toxicology of cyclosporine in humans and animals. Pharmacol. Rev., 42, 423-434.
28. MERVAALA, E.M.A., LASSILA, M., VASKONEN, T., KROGERUS, L., LÄHTEENMÄKI, T., VAPAATALO, H. & KARPPANEN, H. (1999). Effects of ACE inhibition on cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on high sodium diet. Blood Pressure, 8, 49-56.
29. MERVAALA, E.M.A., PAAKKARI, I., LAAKSO, J., NEVALA, R., TERÄVÄINEN, T.-L., FYHRQUIST, F., VAPAATALO, H. & KARPPANEN, H. (1994). Replacement of salt by a novel potassium-and magnesium-enriched salt improves the cardiovascular effects of ramipril. Br. J. Pharmacol., 111, 1189-1197.
30. MERVAALA, E.M.A., PERE, A.-K., LINDGREN, L., LAAKSO, J., TERÄVÄINEN, T-L., KARJALA, K., VAPAATALO, H., AHONEN, J. & KARPPANEN, H. (1997). Effects of dietary sodium and magnesium on cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats. Hypertension, 29, 822-827.
31. MURRAY, B.M. PALLER, M.S. & FERRIS, T.F. (1985). Effect of cyclosporine administration on renal hemodynamics in concious rats. Kidney Int., 28, 767-774.
32. MYERS, B.D., SIBLEY, R., NEWTON, L., TOMLANOVICH, S.J., BOSHKOS, C., STINSON, E., LUETCHER, J.A., WHITNEY, D.J., KRASNY, D., COPLON, N.S. & PERLEROTH, M.G. (1988). The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int., 33, 590-600.
33. NOBLE, N.A. & BORDER, W.A. (1997). Angiotensin II in renal fibrosis: Should TGF-β rather than blood pressure be the therapeutic target? Semin. Nephrol., 17, 455-466.
34. OKUNISHI, H., OKA, Y., SHIOTA, N., KAWAMOTO, T., SONG, K. & MIYAZAKI, M. (1993). Marked species-difference in the vascular angiotensin II-forming pathways: human versus rodents. Jpn. J. Pharmacol., 62, 207-210.
35. ORIJI, G.K. & KEISER, H.R. (1998). Role of nitric oxide in cyclosporine A-induced hypertension. Hypertension, 32, 849-855.
36. O'SULLIVAN, J.B & HARRAP, S.B. (1995). Resetting blood pressure in spontaneously hypertensive rats: the role of bradykinin. Hypertension, 25, 162-165.
37. PERE, A.-K., KROGERUS, L., MERVAALA, E.M.A., LAAKSO, J., KARPPANEN, H., INKINEN, K., PERE, P., AHONEN, J., VAPAATALO, H. & LINDGREN, L. (1998). Detrimental effect of dietary sodium and beneficial effect of dietary magnesium on glomerular changes in cyclosporin A-treated spontaneously hypertensive rats. Nephrol. Dial. Transplant., 13, 904-910.
38. PICHLER, R.H., FRANCESCHINI, N., YOUNG, B.A., HUGO, C., ANDOH, T.F., BURDMANN, E.A., SHANKLAND, S.J., ALPERS, C.E., BENNETT, W.M., COUSER, W.G. & JOHNSON, R.J. (1995). Pathogenesis of cyclosporine nephropathy: Roles of angiotensin II and osteopontin. J. Am. Soc. Nephrol., 6, 1186-1196.
39. REGITZ-ZAGROSEK, V., AUCH-SCHWELK, W., HESS, B., KLEIN, U., DUSKE, E., STEFFEN, C., HILLDEBRANDT, A.G. & FLECK, E. (1995). Tissue-and subtype-specific modulation of angiotensin II receptors by chronic treatment with cyclosporin A, angiotensin-converting enzyme inhibitors and ATI antagonists. J. Cardiovasc. Pharmacol., 26, 66-72.
40. RUMP, L.C., BERLIT, T., SCHWETFEGER, E., BEYERSDORF, F., SCHOLLMEYER, P. & BOHMAN, C. (1997). Angiotensin converting enzyme inhibition unmasks the sympathofacilitary effect of bradykinin in human right atrium. J. Hypertens., 15, 1263-1270.
41. SENNESAEL, J., LAMOTE, J., VIOLET, I., TASSE, S. & VERBEELEN, D. (1995). Comparison of perindopril and amlodipine in cyclosporine-treated renal allograft recipients. Hypertension, 26, 436-444.
42. SUSSMAN, M.A., LIM, H.W., GUDE, N., TAIGEN, T., OLSON, E.N., ROBBINS, J., COLBERT, M.C., GUALBERTO, A., WIECZOREK, D.F. & MOLKENTIN, J.D. (1998). Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science, 281, 1690-1693.
43. TAKEDA, Y., MIYAMORI, I., WU, P., YONEDA, T., FURUKAWA, K. & TAKEDA, R. (1995). Effects of an endothelin receptor antagonist in rats with cyclosporine-induced hypertension. Hypertension, 26, 932-936.
44. WANG, C., FORD, P., CHAO, C., CHAO, L. & CHAD, J. (1997). Effect of cyclosporin A on the expression of tissue kallikrein, kininogen and bradykinin receptor in rat. Am. J. Physiol., 273 (5 Pt 2), F783-F789.
45. YAMAMOTO, S., HAYASHI, N., KOMETANI, M., NAKAO, K. & INUKAI, T. (1997). Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 1st communication: antihypertensive effect of valsartan in hypertensive models. Arzneim.-Forsch./Drug Res., 47, 604-612.